Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags Linker-payload

Tag: linker-payload

Araris Biotech and Taiho Pharmaceutical to Jointly Develop Next-Generation ADCs

ADC Review | Editorial Team
Swiss oncology-focused Araris Biotech, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, which is pioneering the development of next generation, proprietary antibody-drug conjugate (ADC)-linker technology, has entered a collaboration agreement with Japanese R&S driven specialty pharma Taiho Pharmaceutical Co.
Magazines heap detail

Site Specific Conjugation of Hydrophobic Payloads Without Genetic Engineering

Peter Hofland
Site-specific conjugation leads to more homogeneous conjugates and allows control of the site of drug attachment. This approach frequently relies on antibody engineering to...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X